Diversigen and Baylor Miraca Genetics Laboratories, a global leader in genetic testing, have established a strategic partnership to provide their respective customers with access to a broad range of microbiome and metagenomics services, as well as targeted genomics and metabolomics services. The two companies, both commercial endeavors of Baylor College of Medicine, are leveraging the scientific acumen and research infrastructure from the renowned College that founded them. Each company will provide access to the services of the other for customers interested in a greater understanding of the host-microbiome relationship.
“Our pharmaceutical customers have expressed an interest in correlating microbiome data with specific host genetic traits to better understand the host-microbiome relationship as a causal factor in disease and in the search for more effective therapies. This partnership with BMGL will allow us to provide broader services resulting in deeper insights into human health and disease.”
President, Diversigen, Inc.
“As we continue to transition from an academically-centered genetic laboratory to a commercial organization focused on advancing patient health, access to the expert microbiome resources of the Diversigen team makes perfect sense,” said Gary Huff, President and CEO of Baylor Miraca.
President and CEO, Baylor Miraca Genetics Laboratories
Diversigen and BioCore Co. Ltd., a leading bioanalytical contract research organization based in South Korea, have established a strategic partnership that expands BioCore’s portfolio by adding Diversigen’s industry-leading microbiome/metagenomics services to BioCore’s already broad list of service offerings. The partnership also facilitates Diversigen’s entry into the rapidly growing Korean pharmaceutical market. BioCore has a long-standing reputation for delivering quality service to their customer base that extends throughout Asia.
BioCore Co., Ltd. provides clinical research services for pharmaceutical, biotechnology, and medical device companies. The company offers bioequivalence test, clinical trial, toxicokinetics, nonclinical trial, pharmacokinetics, analytical method validation, and comparative dissolution test services. BioCore also provides project strategic planning, clinical research, monitoring, data management, statistical analysis, medical translation, quality assurance, and product development and registration consulting services. BioCore Co., Ltd. was founded in 2011 and is headquartered in Seoul, South Korea.
“Our partnership with Diversigen gives BioCore an opportunity to broaden our reach in the Korean pharmaceutical market and provide our customers with access to the leading scientists in the exploding field of microbiome research.”
Dr. H.S. Choie
President and CEO , BioCore Co. Ltd
“BioCore offers the best in a strategic partner – deep domain expertise, a solid reputation, and an innovative approach to serving their customers. We look forward to helping BioCore and their customers gain competitive advantage through solutions designed to accelerate and transform discovery research, accelerate otherwise lengthy clinical trials, and capitalize on the diverse opportunities of the microbiome.”
President, Diversigen Inc.